These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
115 related items for PubMed ID: 18539915
1. Redefining quality--implications of recent clinical trials. Krumholz HM, Lee TH. N Engl J Med; 2008 Jun 12; 358(24):2537-9. PubMed ID: 18539915 [No Abstract] [Full Text] [Related]
2. [Too positive comment on glitazones]. Lindberg M. Ugeskr Laeger; 2007 Feb 19; 169(8):733; author reply 733. PubMed ID: 17338040 [No Abstract] [Full Text] [Related]
3. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease. Ragucci E, Zonszein J, Frishman WH. Heart Dis; 2003 Feb 19; 5(1):18-33. PubMed ID: 12549986 [Abstract] [Full Text] [Related]
4. [Arterial risk in type 2 diabetes: from mega-trials to prescription]. Bonnet F, Moulin P. Rev Prat; 2003 May 15; 53(10):1095-101. PubMed ID: 12846030 [Abstract] [Full Text] [Related]
5. [Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view]. MMW Fortschr Med; 2008 Aug 28; 150(32-35):56-7. PubMed ID: 19009700 [No Abstract] [Full Text] [Related]
6. [How does the PROactive Study change therapy of diabetes?]. Erdmann E. MMW Fortschr Med; 2005 Oct 13; 147(41):6. PubMed ID: 16270501 [No Abstract] [Full Text] [Related]
7. [Type 2 diabetics are high risk patients. Concerning LDL-cholesterol to approach effectively to two sources]. MMW Fortschr Med; 2005 Nov 03; 147(44):52-3. PubMed ID: 16302495 [No Abstract] [Full Text] [Related]
8. [Trends in diabetes]. Ruiz J, Egli M. Rev Med Suisse; 2008 Jan 16; 4(140):116, 118-21. PubMed ID: 18309874 [Abstract] [Full Text] [Related]
9. Metformin: diamonds are forever. Papanas N, Maltezos E, Mikhailidis DP. Expert Opin Pharmacother; 2009 Oct 16; 10(15):2395-7. PubMed ID: 19678795 [Abstract] [Full Text] [Related]
10. [Glitazones critically evaluated]. Schernthaner G. Dtsch Med Wochenschr; 2007 Dec 16; 132(49):2619. PubMed ID: 18050024 [No Abstract] [Full Text] [Related]
11. Incretins: cardiovascular safety and rationale for use. Kok A. Cardiovasc J Afr; 2013 Mar 16; 24(2):46. PubMed ID: 23750348 [No Abstract] [Full Text] [Related]
12. Therapy and clinical trials: glycaemic control and cardiovascular disease. Edavalath M, Rees A. Curr Opin Lipidol; 2009 Dec 16; 20(6):530-1. PubMed ID: 19935205 [No Abstract] [Full Text] [Related]
13. Drugs for type 2 diabetes mellitus: the imperative for cardiovascular outcome assessment. Gore MO, McGuire DK. Diab Vasc Dis Res; 2012 Apr 16; 9(2):85-8. PubMed ID: 22496441 [No Abstract] [Full Text] [Related]
14. Diabetes drugs pass cardiovascular risk check. Opar A. Nat Rev Drug Discov; 2009 May 16; 8(5):343-4. PubMed ID: 19404302 [No Abstract] [Full Text] [Related]
15. Cardiovascular trials and diabetes treatments: a regulatory maze. Matthews DR. Diab Vasc Dis Res; 2012 Apr 16; 9(2):83-4. PubMed ID: 22419242 [No Abstract] [Full Text] [Related]
16. [Glitazones--a new class of drugs in treatment of type 2 diabetes]. Kleinwechter H. Dtsch Med Wochenschr; 2002 Feb 22; 127(8):400-1. PubMed ID: 11859452 [No Abstract] [Full Text] [Related]
17. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB. Pharmacotherapy; 2006 Feb 22; 26(2):168-81. PubMed ID: 16466323 [Abstract] [Full Text] [Related]